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What We Already Know about This Topic
• The antidepressant effect of ketamine is associated with increased 
activity in the reward circuitry of the brain and a suppression of 
circuitry that mediates perceptual processing of negative emotions. 
The duration of ketamine effect on these brain structures remains 
to be defined.
What This Article Tells us That Is New
• As expected, ketamine administration led to an improvement in 
mood and global vigilance. The improvement in mood was accom-
panied by an increased recruitment of the orbitofrontal cortex, ven-
tral striatum, medial substantial nigra and ventral tegmental area, 
structures that are part of the reward circuitry.
• Responses in the mesolimbic structures (amygdala, medial 
substantial nigra and ventral tegmental area, orbitofrontal 
cortex) to negative stimuli were decreased after ketamine 
administration.
• The data are consistent with the premise that ketamine induces 
sustained changes in the mesolimbic neural circuits to reset 
pathological reward and emotional processing.
Major depressive disorder is a seriously debilitating condition.1 Anhedonia and impaired recognition of 
emotional stimuli are major hallmarks of depression and 
could be involved in the emergence of maladaptive mood 
states. Anhedonia, the inability to experience pleasure 
from activities usually found enjoyable, is accompanied 
by decreased motivation or drive, and functional mag-
netic resonance imaging together with positron emission 
tomography studies have revealed altered neural activity 
in several components of the reward circuitry in patients 
with major depressive disorder.2–4 Abnormal perceptual 
processing of emotional valence, such as attentional bias 
away from or reduced sensitivity to happy facial expres-
sions, are thought to reflect reduced functional connec-
tivity and feedback between certain cortical and limbic 
brain structures.5,6
aBStract
Background: Ketamine rapidly improves maladaptive mood states in major 
depressive disorder, and some of the neural substrates underlying this ther-
apeutic effect have been identified. This study aimed to identify functional 
changes within neural networks that may underlie the impact of ketamine on 
both reward and emotional processing in patients with treatment-resistant 
major depression.
Methods: Ten adult patients with a Montgomery–Åsberg Depression Rating 
Scale score above 25 were enrolled to receive a single intravenous admin-
istration of ketamine (0.5 mg/kg). Patients’ performance along with related 
neural network activations were analyzed in a game-like reward task and in 
an emotional judgment task using functional magnetic resonance imaging 1 
day before and 1 and 7 days after ketamine administration.
results: A significant correlation (R2 = 0.46, P = 0.03) between the improve-
ment of depression scores and the enhanced reaction time for positive items 
was found in the game-like reward task 1 day after ketamine administration. 
This enhanced sensitivity for rewarded items was accompanied by increased 
activity of reward-related brain regions, including the orbitofrontal cortex, ven-
tral striatum, and the ventral tegmental area, an effect that persisted up to 1 
week after ketamine injection. In the emotional judgment task, it was found 
that ketamine rapidly modified local brain activities in response to emotionally 
negative, positive, or neutral stimuli in the amygdala, insula, anterior cingulate 
cortex, and in the ventral tegmental area.
conclusions: Single bolus ketamine administration rapidly triggers lasting 
changes in mesolimbic neural networks to improve pathologic reward and 
emotional processing in patients with major depressive disorder.
(ANESTHESIOLOGY 2019; 130:923–35)
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The clinical effectiveness of currently approved pharma-
cologic approaches to treat major depressive disorder is seri-
ously hampered by the fact that these drugs may need several 
weeks to provide therapeutic effects, and that they operate 
with a relatively low rate of clinical effectiveness along with 
a high incidence of relapse.7 In pioneering studies, low sub-
anesthetic concentrations of ketamine rapidly and signifi-
cantly alleviated depressive symptoms in patients resistant to 
classic pharmacologic antidepressant medications.8,9 These 
initial findings were confirmed by subsequent clinical trials, 
and recent meta-analyses unanimously support the antide-
pressant therapeutic potential of ketamine.10,11
Identifying the neural substrates involved in the antide-
pressant effects of ketamine will provide us with import-
ant new information about the neurobiology of depression 
and, ultimately, regarding mood disorder therapeutics. 
Recent investigations in patients with major depressive 
disorder revealed no change in whole brain metabolism 2 
hours after ketamine injection, whereas a priori region of 
interest analysis showed acute ketamine-induced alterations 
in the activity levels of several brain structures specifically 
involved in emotional and reward processing.12–17 However, 
we currently do not know whether and to what extent 
the ketamine-induced changes in network activities per-
sist over time. A related important series of yet-unexplored 
questions concern the impact of ketamine on both reward 
and emotional processing in these patients, and how func-
tional changes within neural networks may explain changes 
in depressive symptoms. The present study aimed to answer 
these questions by acquiring whole-brain functional mag-
netic resonance imaging data in 10 treatment-resistant 
patients with major depressive disorder while they per-
formed a game-like reward task18 and an emotional judg-
ment task19 up to 1 week after a single ketamine injection. 
We hypothesized that ketamine would normalize responses 
within emotion and reward brain networks, including the 
amygdala, insula, anterior cingulate cortex, orbitofrontal 
cortex, ventral striatum, and ventral tegmental area.20–23
Materials and Methods
This open uncontrolled pilot study was conducted at the 
Geneva University Hospitals, Geneva, Switzerland, in accor-
dance with local and national legislation, and the Declaration 
of Helsinki.24 The study protocol was approved by the local 
ethics committee and registered in the clinicaltrials.gov 
database (NCT01135758). The primary objective of the 
study protocol was to confirm the robust and rapid anti-
depressant effects of intravenously administered ketamine 
(0.5 mg/kg) using the Montgomery–Åsberg Depression 
Rating Scale as a primary outcome measure at baseline 
and after distinct time intervals of ketamine injection.25 A 
secondary objective of the study protocol, reported specif-
ically in the present manuscript, was to examine changes 
in regional cerebral blood flow induced by ketamine using 
functional magnetic resonance imaging. All patients gave 
written informed consent before any assessment. No a priori 
statistical power calculation was conducted.
Participants
Ten patients (four men, 38 to 58 yr of age; see table  1 
for detailed patients’ characteristics) were recruited from 
the Department of Mental Health and Psychiatry of the 
University Hospital of Geneva using the following inclu-
sion criteria: (1) Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision diagnostic criteria 
for recurrent major depressive disorder without psychotic 
features, (2) the absence of Axis I psychiatric comorbid-
ities except anxiety disorder, (3) no lifetime history of 
psychotic symptoms nor bipolar disorder, (4) no sub-
stance abuse or dependence in the previous 3 months 
(except nicotine consumption), (5) a score of 25 or higher 
on the Montgomery–Åsberg Depression Rating Scale 
(MADRS),26 (6) unchanged medication (antidepressants, 
antipsychotics, mood stabilizers) during the last 6 weeks 
before inclusion, and (7) failure of at least two adequate 
antidepressant treatments (i.e., 4 weeks at the maximal 
authorized or tolerated dose). Exclusion criteria included 
(1) serious and imminent risk of suicide (score at or above 
4 on item 10 of the MADRS), and (2) any contraindication 
to the administration of ketamine or to undergo magnetic 
resonance imaging scanning. All patients participated in the 
entire protocol, and there were no missing data.
Experimental Procedure
Upon inclusion to the protocol and receipt of their writ-
ten informed consent, patients were scheduled for four 
visits: one for the administration of a single dose of ket-
amine (DAY 0), and three magnetic resonance imaging ses-
sions performed one day before (DAY−1), one day after 
(DAY+1), and seven days after (DAY+7) ketamine admin-
istration (fig. 1A). This experimental design allowed us to 
compare baseline (DAY−1) with early (DAY+1) and late 
(DAY+7) effects of ketamine on brain function.
Ketamine administration occurred at the Clinical 
Research Center, University Hospital of Geneva, 
Switzerland. Upon arrival, depression level was assessed 
in each patient using the clinician-administered MADRS, 
the Hamilton Depression Rating Scale (HDRS-21),27 and 
the Beck Depression Inventory (BDI-II) scales.28 A clinical 
monitoring (pulse, blood pressure, digital pulse oximetry, 
and electrocardiogram) was then set to control physiologic 
parameters during and shortly after ketamine injection. 
Ketamine hydrochloride (0.5 mg/kg) was administered by 
a senior anesthesiologist in a bolus injection over 1 min 
via a dorsal hand vein of the nondominant arm. To con-
trol for potential adverse events after ketamine administra-
tion, patients were monitored at the clinical research unit 
for 4 h after the injection. Although all patients displayed 
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a transient increase in blood pressure, none needed phar-
macologic intervention to reduce this. In line, none of the 
patients displayed any major adverse events necessitating 
clinical intervention. Six of the 10 patients displayed tran-
siently altered vigilance lasting less than 15 min. To assess the 
rapid effect of ketamine on self-reported depression level, 
the depression scales were further assessed 60 min before 
and 40, 80, 110, and 230 min after ketamine injection.
The three magnetic resonance imaging sessions were 
conducted at the Brain and Behavior Laboratory, University 
of Geneva, Switzerland. The protocol included a three- 
dimensional T1-weighted whole brain structural image and 
two event-related functional magnetic resonance imaging 
scans during which patients performed a reward task and an 
emotional judgment task (see below). Patients arrived at 9 am 
and were screened for changes in their clinical assessment by 
a psychiatrist. Their depression level was again assessed using 
the MADRS, HDRS-21, and BDI-II scales. Then, before the 
first session, they received detailed instructions relative to the 
magnetic resonance imaging protocol and performed a demo 
version of the two tasks on a computer outside the magnetic 
resonance imaging scanner, to familiarize the patients with 
the tasks and minimize any potential learning effect during 
the following magnetic resonance imaging sessions. They 
were next placed into the magnetic resonance imaging scan-
ner and performed the full versions of both tasks.
Experimental Tasks and Behavioral Analysis
Reward Task 
The reward task was a game-like task, adapted from the 
Monetary Incentive Delay task.18 In this task, patients 
could win or lose points by rapidly pressing a key when 
a visual target was shown. Each trial started with the 
table 1.  Sociodemographic and Clinical Characteristics  





Sociodemographic parameters  
 Female 6
 Age, yr 51 (38–58)
 Education, yr 14 (9–18)
 Married 4
 Currently unemployed 9
 Living alone 3
Psychiatric diagnosis (DSM-V code)  
 Major depressive disorder, recurrent, severe 
without psychotic features (296.33)
9
 Major depressive disorder, single episode, 
severe without psychotic features (296.23)
1
 Persistent depressive disorder (300.4) 8
 Anxiety disorders 9
 Social anxiety disorder (300.23) 2
 Specific phobia (300.29) 1
 Panic disorder (300.01) 4
 Generalized anxiety disorder (300.02) 4
 Obsessive-compulsive disorder (300.3) 1
 Posttraumatic stress disorder (309.81) 1
 unspecified anxiety disorder (300.00) 1
History of illness  
 Age of onset, yr 27 (18–51)
 Duration of major depressive disorder, yr 21 (4–29)
 Number of major depressive episodes 3 (1–5)
 Prior suicide attempt 4
Current depressive episode  
 Episode duration, months 47 (9–204)
 Hospitalization during current episode 6
Psychotropic medication  
 Antidepressants 10
 Antipsychotics 7
 Mood stabilizers 5
 Benzodiazepines 10
DSM-V, Diagnostic and Statistical Manual of Mental Disorders, 5th edition.
Fig. 1. Overall experimental design and depression scores. (A) Experimental design. (B) Evolution of the level of depression over the three 
visits and for different mood scales (mean ± SD). BDI, Beck Depression Inventory; D, day; HDRS, Hamilton Depression Rating Scale; MADRS, 
Montgomery–Åsberg Depression Rating Scale.
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presentation of a cue indicating whether this trial could 
result in more points for successful performance (vs. no 
additional points if unsuccessful; positively cued trials, +1 
or +5 points) or in an actual loss for unsuccessful perfor-
mance (vs. no loss if successful; negatively cued trials, −1 
or −5 points). The cue was presented for 1,200 ms and 
then blinked for 1,125 ms (the coin was flipped horizon-
tally at 4 Hz). After a variable delay (mean ± SD: 1,375 ms 
± 875 ms), the visual target requiring a rapid key press 
was briefly shown on the screen. Any response occurring 
before (anticipated response) or after (late response) tar-
get presentation, as well as the absence of a response was 
considered as an unsuccessful trial. The trial ended with 
a feedback display indicating whether the trial was won 
or lost. We could thus distinguish brain activity during 
the anticipation period (presentation of the cue) and the 
outcome period (presentation of the feedback). We also 
compared positively cued trials (+1 and +5; i.e., potential 
gains) to negatively cued trials (−1 and −5; i.e., potential 
losses) during the anticipation phase, as well as successful 
to unsuccessful trials during the feedback period. Each of 
the four cue types was presented 30 times in random order. 
To obtain an equal proportion of successful and failed tri-
als as well as to match task difficulty across participants 
and sessions, the target’s presentation time was adjusted 
based on the participant’s current performance: whenever 
the trial was successful or unsuccessful, 25 ms were sub-
tracted or added to the presentation time of the next trial 
with identical cue type, respectively. Performance on the 
task was analyzed using the percentage of correct trials 
(hits), the percentage of late responses (trials for which the 
patient responded after the disappearance of the target), 
and the mean reaction times for correct trials, for each cue 
type. We used three-way repeated-measures ANOVA in 
Statistica 11.0 (StataCorp 2009, Stata Statistical Software: 
Release 11, StataCorp LP, USA), including Session (DAY-
1, DAY+1, DAY+7), Cue Valence (positive, negative), and 
Cue Value (1 point, 5 points) as within-subjects factors. 
Post hoc analyses were performed using planned com-
parisons corrected for multiple comparisons with the 
Bonferroni method. Specifically, we tested for differences 
across sessions (DAY−1 vs. DAY+1, DAY−1 vs. DAY+7 
and DAY+1 vs. DAY+7) for high positive cues. These 
comparison tests directly derive from our main hypothe-
sis about the restoration of adapted emotional response to 
rewarded stimuli after ketamine injection. Finally, we also 
wanted to test whether the modification of depression 
scores was correlated with the modification of behavioral 
performances. We performed a correlation between the 
evolution of depression (MADRS score) by ketamine and 
the evolution of reaction times for positive items.
Emotional Judgment Task 
The emotional judgment task was adapted from Sterpenich 
et al.19 In this task, patients were asked to rate the emotional 
valence of pictures. Each trial started with the presentation 
of a fixation cross on a gray screen (1,000 ms), followed by 
the presentation a picture (3,000 ms). The trial ended with 
a choice display (2,000 ms), during which the patients were 
asked to rate the valence of the picture on a four-point 
scale (from very negative to very positive), using a rating sys-
tem inspired by the Self-Assessment Manikin.29 In each ses-
sion, a total of 90 different photographs were selected based 
on the ratings from 12 healthy volunteers and included 30 
negative (consisting in aversive scenes), 30 neutral, and 30 
positive (consisting of humorous scenes) pictures. The set 
of stimuli for each emotional category contained a simi-
lar proportion of objects, landscapes, animals, and human 
beings. Moreover, the three sets of stimuli used for the three 
sessions were matched for emotional ratings. Picture lumi-
nance was equalized to obtain the same mean luminance 
for all pictures. The pictures were presented one at a time 
and in random order. For subsequent behavioral (and func-
tional magnetic resonance imaging) analyses, each trial was 
categorized based on each individual’s subjective ratings: 
‘−2’ ratings were assigned to the negative condition, ‘−1’ 
and ‘+1’ ratings were grouped into a neutral condition, and 
‘+2’ ratings were assigned to a positive condition. The pro-
portion and reaction times of pictures judged emotionally 
negative, neutral, and positive were analyzed using two-
way repeated-measure ANOVAs with Session (DAY−1, 
DAY+1, DAY+7) and Emotional Valence (negative, neutral, 
or positive) as within-subject factors.
For both tasks, stimuli were projected by a LCD projector 
(CP-SX1350, Hitachi, Japan) on a screen (about 19° × 14°) 
placed inside the scanner bore. Key presses were recorded on 
an magnetic resonance imaging-compatible response button 
box (HH-2 × 4-C, Current Designs Inc., USA).
For the analysis of the depression scales, we performed 
three separate one-way ANOVAs, one for each depression 
scale measured at three time points (i.e., sessions). Post hoc 
Bonferroni analysis revealed significant differences between 
sessions.
Magnetic Resonance Imaging Acquisition and Analysis
Magnetic resonance imaging data were acquired on a 
3-T Siemens Trio whole-body scanner (Siemens Medical 
Solutions, Germany) using an eight-channel head coil, at 
the Brain and Behavior Laboratory, University of Geneva, 
Switzerland. The protocol included a three-dimensional 
T1-weighted whole brain structural image (192 con-
tiguous sagittal slices; repetition/echo time/flip angle: 
1,900 ms/2.27 ms/9°; field of view: 256 mm; matrix: 256 × 
256 × 192; voxel-size: 1 × 1 × 1 mm). This acquisition vol-
ume was aligned on the anterior/posterior commissure axis, 
localized on the mid-sagittal slice of a localizer scan. For each 
participant, one three-dimensional T1-weighted structural 
images was normalized using the T1 Montreal Neurological 
Institute template of SPM8  (Wellcome Department 
of Imaging Neuroscience, London, United Kingdom; 
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http://www.fil.ion.ucl.ac.uk/spm, accessed September 15, 
2018). Functional images of the two tasks were acquired with 
a gradient-echo echo-planar imaging sequence (repetition/
echo time/flip angle: 2,100 ms/30 ms/80°; field of view: 
205 mm, matrix: 64 × 64 × 36, gap 20%: 0.6mm, slice acqui-
sition order: descending) and parallel imaging (GeneRalized 
Autocalibrating Partial Parallel Acquisition [GRAPPA], accel-
eration factor = 2). A total of 385 and 290 magnetic resonance 
imaging volumes in each session were acquired for the reward 
task and the emotional judgment task, respectively. Each func-
tional image comprised 36 axial slices (voxel-size: 3.2 × 3.2 × 
3.2 mm) oriented parallel to the inferior edge of the occipital 
and temporal lobes, and covering the whole brain.
Functional magnetic resonance imaging data were ana-
lyzed using SPM8. Images were realigned to the mean 
functional image of the corresponding task, then cor-
rected for slice timing, normalized to an EPI template in 
MNI space (re-sampled voxel-size of 3 mm), and spatially 
smoothed (8 mm full width at half maximum  Gaussian 
kernel). Statistical analysis were performed using the gen-
eral linear model implemented in SPM8, with separate 
regressors for each event-type convolved with a canonical 
hemodynamic response function.
The statistical model of the reward task included 16 main 
regressors of interest: eight regressors with events time-
locked to the presentation of the cue (anticipation period) 
for the four cue types further subdivided into subsequently 
successful or unsuccessful trials (four cue types × two possi-
ble feedbacks), and eight regressors with events time-locked 
to the presentation of the feedback (outcome period) also 
subdivided as a function of cue type and feedback. All tri-
als with anticipated responses (keypresses before the target 
presentation) and trials with no responses, representing less 
than 1.5% of the total number of responses, were grouped 
into two regressors (cue onset and feedback onset) of no 
interest. The contrasts of interest for the reward task were 
the interactions between positive emotions ([positive cues 
greater than negative cues] or [positive feedbacks greater 
than negative feedbacks]) and ketamine sessions ([DAY+1 
greater than DAY−1] and [DAY+7 greater than DAY−1]). 
The reverse contrasts were also presented ([DAY−1 greater 
than DAY+1] and [DAY−1 greater than DAY+7]). The 
main effects of emotions and ketamine sessions were not 
presented here because they are not relevant to the main 
hypothesis.
The statistical model of the emotional judgment task 
included three main regressors of interest: the presentation 
of negative, positive, and neutral pictures. For both models, 
movement parameters from realignment corrections were 
entered as additional covariates of no interest to account for 
residual movement artefacts. The contrasts of interest for the 
emotional judgment task were the interactions between posi-
tive emotions ([positive images greater than negative images]) 
and ketamine sessions ([DAY+1 greater than DAY−1] and 
[DAY+7 greater than DAY−1]). The reverse contrasts were 
also presented ([DAY−1 greater than DAY+1] and [DAY−1 
greater than DAY+7]). The main effects of emotions (positive 
greater than neutral and negative greater than neutral) and 
ketamine sessions were not presented here because they are 
not relevant to the aim of the study.
For each task, individual statistical parametric maps 
were generated from linear contrasts between condi-
tions. These contrast maps then entered second-level ran-
dom-effect analyses using one-sample t tests. Statistical 
inferences were corrected for multiple comparisons using 
Gaussian random field theory at the voxel level. For the 
whole brain analysis, brain activations were detected at 
a voxel-level of P ≤ 0.001 (uncorrected) with a cluster 
size greater than or equal to 5 voxels. If the peak of the 
regions observed at this threshold did not survive to the 
correction for multiple comparison for the entire brain 
(P < 0.05 family-wise error correction), we applied the cor-
rection for multiple comparison on a smaller volume using 
the small volume corrections procedure in SPM. Based on 
the relevant literature,20–23 we created anatomical masks 
from automated anatomical labeling30 for regions specifi-
cally involved in reward and emotion processing, including 
amygdala, insula, anterior cingulate cortex, orbitofrontal 
cortex, and ventral striatum. Other activated regions for 
which we had no a priori hypothesis are not reported here. 
In this case, we reported brain activations for regions pres-
ent at P < 0.001 uncorrected and significant at P < 0.05 
family-wise error correction using the small volume cor-
rections procedure on these selected maks at the voxel level 
for the peak of the region.
In addition, after the whole-brain analysis, we performed 
a more specific analysis on a particular region. Because we 
were interested in changes across the dopaminergic reward 
system and because reward processing involves midbrain 
dopaminergic neurons,31 we performed a region of inter-
est analysis. We extracted directly functional magnetic res-
onance imaging signal from the medial substantia nigra/
ventral tegmental area using a mask generated in a previous 
study in 19 healthy human volunteers and based on a pro-
ton density–weighted sequence.32 The extracted functional 
magnetic resonance imaging signal corresponds to the 
mean of the parameter estimates (beta values) of all voxels 
of the anatomical region. The extracted data were calcu-
lated for each condition, and we analyzed the extracted data 
using a two-way repeated-measures ANOVA (Emotion by 
Session) in Statistica.
Finally, we wanted to test whether the modifications of 
brain activations attributable to ketamine were similar or 
not after short and long delay. We displayed the contrast of 
interest (positive vs. negative for the different tasks) for the 
short delay (DAY+1 vs. DAY−1), and we masked it inclu-
sively with the similar contrast for long delay (DAY+7 vs. 
DAY−1) to identify the brain regions that were common to 
both contrasts. The small volume corrections procedure was 
then performed on the resulting data.
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Impact of Ketamine on Depression Scales
In line with previous observations,10,11 three separate 
one-way repeated-measures ANOVAs on the HDRS-21, 
MADRS, and BDI-II scales showed that depression scores, 
high before ketamine injection (DAY−1), significantly 
decreased both rapidly (DAY+1) and lastingly (DAY+7) 
after intravenous ketamine (0.5 mg/kg) administration 
(main effect of Session, all P < 0.006; see fig. 1B). Post hoc 
Bonferroni analyses revealed that these depression scores 
were significantly lower both at DAY+1 and DAY+7 when 
compared independently with DAY−1 (DAY+1 vs. DAY−1: 
HDRS-21: P < 0.001, MADRS: P < 0.001, BDI-II: 
P = 0.008; DAY+7 vs. DAY−1: HDRS-21: P < 0.001, 
MADRS: P < 0.001, BDI-II: P = 0.027). No difference was 
observed when comparing DAY+1 and DAY+7 (HDRS-21: 
P = 1.000, MADRS: P = 0.339, BDI-II: P = 1.000).
Effects of Ketamine on the Game-like Reward Task
Behavioral Performance 
We first set out to examine whether and how ketamine 
administration affected behavioral performance in patients 
with major depressive disorder using the game-like reward 
task (fig. 2A). As seen in table 2, ketamine injection resulted 
in a reduction of late responses in our patient population 
(main effect of Session: F(2,18) = 4.151, P = 0.033). There 
was also a main effect of cue type (high vs. low), F(1,9) = 
9.094, P = 0.015, no main effect of valence F(1,9) = 1.308, P 
= 0.282, and no triple interaction F(2,18) = 2.34, P = 0.13. 
However, the interactions between each session after versus 
the session before ketamine (DAY+1 vs. DAY−1 and DAY+7 
vs. DAY−1) and cue type for positive value were significant 
([DAY+1 vs. DAY−1, cue+5 vs. cue+1, F(1,9) = 6.259, 
P = 0.034] and ([DAY+7 vs. DAY-1, cue+5 vs. cue+1, 
F(1,9) = 9.704, P = 0.012]). This interaction is explained 
by a significant decrease in the number of late responses for 
Fig. 2. Reward task. (A) Illustration of one trial of the reward task, here a successful highly rewarded trial. (B) Percentage of late responses 
for high positive (+5) and negative cues (−5) across the different sessions (mean ± SD). Insula (C) and ventral (D) striatum activation for 
positive versus negative cue presentations. (E) Ventral striatum and medial substantia nigra/ventral tegmental area (F) activation for success-
ful versus lost feedback presentations. For display purposes, brain responses are displayed at P = 0.005 uncorrected, and projected on the 
mean structural image, with parameter estimates of activation plotted on the bottom (mean ± SD). MRI, parameter estimates; mSN, medial 
substantia nigra; Neg, negative; Pos, positive; ROI, region of interest; Suc, success; VTA, ventral tegmental area.
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highly positively cued trials (i.e., cues +5) when compar-
ing both DAY+1 and DAY+7 session independently with 
DAY−1 session (post hoc pairwise comparison, Bonferroni-
corrected for multiple testing, DAY+1 vs. DAY−1: P = 
0.042; DAY+7 vs. DAY−1: P = 0.035, DAY+1 vs. DAY+7: 
P = 0.225; fig. 2B). Besides the effects of ketamine on task 
performance, two-way repeated measure ANOVA (with 
Emotion and Session as within-subjects factors) comparing 
reaction times for these correct responses revealed a main 
effect of Session, F(2,18) = 10.7, P = 0.001: patients being 
faster both at DAY+1 (P = 0.003) and DAY+7 (P = 0.009) 
when compared independently with DAY−1, an effect of 
emotion, F(3,27) = 3.56, P = 0.027, with no significant 
Emotion by Session interaction, F(6,54) = 0.53, P = 0.785. 
To control for any potential training effects during the par-
adigm, we also selectively analyzed the second half of each 
session and found similar results further supporting that our 
observations are due to ketamine administration itself and 
not learning effect. Finally, we observed a significant cor-
relation (R2 = 0.466, P = 0.029) between the improvement 
of depression by ketamine after one day (measured by the 
difference of MADRS scale between DAY−1 and DAY+1) 
and the improvement of reaction time for positive items 
(measure by the difference between DAY−1 and DAY+1 
reaction times for positive vs. negative cues). Taken together, 
these results indicate that ketamine administration increases 
global vigilance level along with specifically enhanced sen-
sitivity for rewarded items.
Functional Magnetic Resonance Imaging To identify neu-
ral networks implicated in ketamine-induced behavioral 
changes in the reward paradigm, we performed whole brain 
analysis using functional magnetic resonance imaging. We 
first tested whether ketamine changed brain activity when 
patients expected a potential reward (positively vs. negatively 
cued trials). During this anticipatory phase, we observed 
rapid ketamine-induced changes in the insula and orbito-
frontal cortex when comparing DAY+1 to DAY−1 sessions 
(fig. 2C; table 3), and in the ventral striatum and orbitofron-
tal cortex when comparing DAY+7 to DAY−1 (fig. 2D). 
Parameter estimates indicated that all these regions were 
more activated for positively than negatively cued trials, 
selectively after ketamine treatment. To further test whether 
ketamine-induced rapid modifications in region-specific 
brain activities persisted over time, we compared brain 
regions at DAY+1 and DAY+7 using the inclusive masking 
procedure. Using this approach, we found that, when com-
pared with DAY−1, orbitofrontal cortex and insula were both 
activated at DAY+1 and DAY+7, suggesting thereby a lasting 
increase in activity after both short- and long-term delays. 
The reverse contrast (positive vs. negative cues, before vs. after 
ketamine) revealed no significant activation, suggesting that 
no particular brain regions exhibited decreased activation for 
rewarded items after ketamine administration.
We next assessed whether ketamine also affected neural 
responses to winning versus losing feedbacks presented during 
the outcome period. When comparing DAY+1 to DAY−1 
sessions, we found an activation of the ventral striatum that 
did not reach significance (xyz mm: -6, 11, 4; z score: 2.44; 
pseudo stokes vector correlation = 0.423) and, when com-
paring DAY+7 with DAY−1 sessions, the same region was 
significantly more activated, together with the orbitofrontal 
cortex (pseudo stokes vector correlation = 0.026, fig. 2E). 
The inclusive masking procedure (DAY+1 vs. DAY−1, and 
DAY+7 vs. DAY−1) revealed that this effect was persistent 
up to one week after injection in the ventral striatum. Again, 
no significant activation was observed in the reverse contrast 
(i.e., for winning vs. losing before vs. after ketamine).
Finally, after the whole brain analysis and to better 
characterize the impact of ketamine on the dopaminergic 
system, we specifically focused on the medial substantia 
nigra/ventral tegmental area as region of interest (anal-
ysis, see Materials and Methods). For the anticipation 
period, extracted functional magnetic resonance imag-
ing data from the substantia nigra/ventral tegmental area 
showed no effect of Session, F(2,18) = 2.560, P = 0.102, 
no effect of Emotion, F(1,9) = 0.002, P = 0.970, and no 
significant Emotion by Session interaction, F(2,18) = 0.132, 
P = 0.877. For the feedback period, we observed no main 
effect of Session, F(2,18) = 1.510, P = 0.0248, and no effect 
of Emotion, F(1,9) = 0.640, P = 0.444). However, the sub-
stantia nigra/ventral tegmental area was more active when 
winning than losing after ketamine administration at both 
posttreatment time points (DAY+1, DAY+7) as compared 
with baseline (DAY−1) (fig. 2F; Interaction comparing suc-
cessful vs. unsuccessful trials and DAY−1 vs. DAY+1 and 
DAY+7, F(2,18) = 6.57, P = 0.031). These results suggest that 
increased reactivity of reward-related regions (orbitofrontal 
cortex, ventral striatum, and medial substantia nigra/ventral 
table 2. Behavioral Results of the Reward Task
day−1 day+1 day+7
 negative cues Positive cues negative cues Positive cues negative cues Positive cues
Hit, % (SD) 50 (3) 52 (3) 51.(3) 53 (2) 53 (3) 54 (3)
Reaction time for hit, ms (SD) 273 (23) 269 (29) 231 (28) 221 (14) 228 (33) 218 (30)
Late response, % (SD) 39 (2) 39 (3) 36 (3) 33 (4) 37 (3) 36 (3)
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tegmental area) during this game-like task could then induce 
a general increase in motivation, which is consistent with the 
faster reaction times observed after ketamine injection.
Effects of Ketamine in the Emotional Judgment Task
Behavioral Performance 
Given the aforementioned effects of ketamine on the 
reward system, we next set to investigate how this drug 
influences the perception of aversive emotions (fig. 3A). 
Using our previously validated emotional judgment task19 
during the three visits, we computed the proportion of 
pictures rated as negative (−3, −2), neutral (−1, 0, +1), or 
positive (+2, +3) for each session. We found a main effect 
of Emotion, F(2,18) = 61.658, P < 0.001, because patients 
scored more neutral pictures than positive or negative ones 
but we showed that ketamine had no significant effect on 
the emotional rating of the pictures (interaction Emotion 
by Session F(4,36) = 2.46, P = 0.063, table 4). However, 
the treatment had a significant main effect on reaction 
times across sessions (effect of Session, F(2,14) = 6.378, 
P = 0.011) because patients were faster after ketamine 
injection (DAY−1 vs. DAY+1 and DAY+7: P = 0.11), but 
no effect of Emotion on reaction times, F(2,14) = 1.014, 
P = 0.389, and no interaction Session × Emotion, F(4,28) 
= 1.037, P = 0.406. This pattern of results converges with 
the results obtained in the reward task to indicate that 
ketamine increased global vigilance.
Functional Magnetic Resonance Imaging 
Using a whole-brain approach, we tested whether ket-
amine modified local brain activity in response to emo-
tionally negative, positive, or neutral stimuli. We found that 
ketamine induced changes in activity for negative versus 
positive pictures. Specifically, when comparing DAY+1 
to DAY−1 sessions, we found that amygdala and insula 
response to negative (vs. positive) pictures strongly decreased 
after ketamine injection (fig. 3, B and C; table 5), whereas 
the reverse contrast showed no significant activation. When 
comparing DAY+7 with DAY−1 session, we observed that 
this decrease persisted in the insula and also in the dorsal 
anterior cingulate cortex. Moreover, the inclusive masking 
procedure revealed that activity in the posterior insula and 
dorsal anterior cingulate cortex decreased significantly after 
both short and long delays (DAY+7 vs. DAY−1, and DAY+1 
vs. DAY−1 contrasts; see Materials and Methods). Here too, 
the reverse contrast revealed no significant activation. These 
results indicate that activity in regions typically implicated 
in the processing of negative emotions was high before ket-
amine injection and decreased after drug treatment.
After the whole-brain approach, and using the same 
region of interest procedure as for the reward task described 
table 3. Brain Activations during the Reward Task
Brain region x y z z score pSvc
Short-term ketamine-induced activity increases for positive cues
(D+1 > D−1, positive > negative)
 Orbitofrontal cortex 21 47 −11 3.87 0.006
 Insula −33 26 −5 3.68 0.041
Short-term ketamine-induced activity decreases for positive cues
(D−1 > D+1, positive > negative)
 No significant activation      
Long-term ketamine-induced activity increases for positive cues
(D+7 > D−1, positive > negative)
 Ventral striatum (NAcc) 18 14 −5 3.77 0.042
 Orbitofrontal cortex −21 38 −14 3.86 0.007
Long-term ketamine-induced activity decreases for positive cues
(D−1 > D+7, positive > negative)
 No significant activation      
Short-term ketamine-induced activity increases for positive feedback
(D+1> D−1, feedback successful > failed)
 No significant activation      
Short-term ketamine-induced activity decreases for positive feedback
(D−1 > D+1, successful > failed)
 No significant activation      
Long-term ketamine-induced activity increases for positive feedback
(D+7 > D−1, successful > failed)
 Ventral striatum (NAcc) 6 8 −8 3.65 0.001
 Orbitofrontal cortex −15 47 −17 3.75 0.011
Long-term ketamine-induced activity decreases for positive feedback
(D−1 > D+7, successful > failed)
 No significant activation      
D, day; NAcc, nucleus accumbens; pSVC, pseudo stokes vector correlation.
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above, we found a striking pattern of activation of the medial 
substantia nigra/ventral tegmental area, with no effect of 
Session, F(2,18) = 0.615, P = 0.552, no effect of Emotion, 
F(2,18) = 0.358, P = 0.704, but a significant interaction 
between Session and Emotion F(4,36) = 3.031, P = 0.030 
(fig.  3D). Specifically, the medial substantia nigra/ventral 
tegmental area was more active for negative than positive 
pictures before treatment (i.e., at DAY−1), whereas it became 
more active for positive than negative pictures at DAY+7 
(negative vs. positive DAY−1 vs. DAY+7: P < 0.001).
discussion
Combining behavioral tests with functional magnetic res-
onance imaging in treatment-resistant patients with major 
depressive disorder, we assessed the rapid (i.e., after one day, 
DAY+1) and lasting (i.e., after 7 days, DAY+7) effects of a 
single bolus ketamine administration on brain responses 
during reward and emotional processing. Our findings sup-
port previous data suggesting that ketamine reduces depres-
sion scores in treatment-resistant major depressive disorder.10,11 
We also show here that ketamine rapidly modified behavior 
and restored brain reactivity in patients with major depressive 
disorder when they were provided with rewarding stimuli and 
when they actively processed emotional pictures, with effects 
persisting at least for one week after drug injection.
Ketamine and Reward Processing
Because dysfunctional reward processing is an important 
hallmark of the pathophysiology of major depressive dis-
order,2 we implemented a monetary incentive delay task 
to evaluate the impact of ketamine on reward function in 
patients with major depressive disorder. This paradigm has 
Fig. 3. Emotional judgment task. (A) Illustration of one trial of the emotional judgment task, here a positive (i.e. humorous) trial. (B) Amygdala, 
(C) insula, and medial substantia nigra/ventral tegmental area increased activity for positive pictures. For display purposes, brain responses are 
displayed at P = 0.005 uncorrected, and projected on the mean structural image, with parameter estimates of activation plotted on the bottom 
(mean ± SD). mSN, medial subtantia nigra; Neg, negative; Neu, neutral; Pos, positive; ROI, region of interest; VTA, ventral tegmental area.
table 4. Behavioral Results of the Emotion Judgment Task
day-1 day+1 day+7
 negative neutral Positive negative neutral Positive negative neutral Positive
Emotional ratings, % of pictures (SD) 23 (2) 64 (4) 13 (3) 24 (2) 60 (6) 16 (5) 21 (3) 72 (4) 8 (3)
Mean reaction time, ms (SD) 701 (47) 799 (44) 870 (101) 612 (58) 657 (61) 671 (83) 576 (47) 650 (48) 567 (41)
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been previously applied across a wide range of psychiat-
ric disorders and, in combination with functional magnetic 
resonance imaging, allows to specifically identify the neu-
ral structures implicated in reward anticipation as well as 
in the feedback response to the anticipated reward.4,18,33–35 
Using this task, we found that the ketamine-induced mood 
improvement in the patients was accompanied by a rapid 
and lasting increase in global vigilance (i.e., decreased reac-
tion times) as well as by better performance for trials associ-
ated with a potential gain, suggesting increased motivation 
or sensitivity to rewards. Indeed, given that reaction times, 
including movement initiation and execution, are deeply 
influenced by motivational factors,36 and that the trials are 
specifically designed to minimize expectancy and habitu-
ation,18 these findings indicate that ketamine administra-
tion rapidly reverses impaired reward processing in patients 
with major depressive disorder. Our behavioral observations 
are also in line with previous studies demonstrating that 
depressed individuals show impaired vigilance and poorer 
memory for positive material37,38 while failing to behavior-
ally respond faster to monetary reward.34,39
These behavioral changes attributable to ketamine 
administration were paralleled by an increased recruitment 
of the orbitofrontal cortex and the ventral striatum both 
during reward anticipation and feedback. These brain struc-
tures are key components of reward processing,40,41 and 
have been shown to display blunted activation patterns in 
major depressive disorder.3,4,42 Because these regions are 
typically activated in healthy volunteers during the pro-
cessing of positively cued trials, our current results suggest 
that ketamine leads to (at least partial) recovery of brain 
reward function in patients with major depressive disorder. 
To further tackle the role of ketamine on the reward sys-
tem in major depressive disorder, we also focused on the 
medial substantia nigra/ventral tegmental area region that 
gives rise to the dopaminergic projections of the mesocor-
ticolimbic pathway.31 Optogenetic inhibition of dopamine- 
releasing neurons in this region have been shown to induce 
depression-related behavior in rodents,43 whereas deep 
brain stimulation of several components of the mesocorti-
colimbic pathway has been reported to improve depressive 
symptoms in pharmacologic treatment-resistant patients 
with major depressive disorder.44,45 The fact that ketamine 
rapidly and persistently increased medial substantia nigra/
ventral tegmental area activity during positively cued trials 
in our study population therefore further supports a role 
of this drug in normalizing reward processing in major 
depressive disorder. Although our study does not allow us 
to draw conclusions on the molecular mechanisms behind 
these effects, experimental evidence indicates that ketamine 
can increase striatal dopamine release.46,47 Such a ketamine- 
induced increase in dopamine could explain increased neu-
ral reactivity to rewards in patients with major depressive 
disorder, as we observed here, which in turn may be respon-
sible for ketamine’s therapeutic effects.
Ketamine and Emotional Processing
We also evaluated the impact of ketamine on the process-
ing of positive and negative emotional stimuli and found 
that ketamine did not induce a detectable shift in the pro-
portion of negatively, neutrally, or positively rated pictures. 
Although we do not have a clear explanation for this, it has 
previously been reported that behavioral biases toward sad 
faces seem to persist even after recovery from depression.48 
An alternative explanation would be that the sensibility of 
the test, offering merely four distinct possibilities of ratings, 
might be too low to detect changes in emotional percep-
tion. We did, however, find a significant improvement in 
reaction times after ketamine injection. These results are 
table 5. Brain Activations during the Emotional Judgment Task
Brain region x y Z z score pSvc
Short-term ketamine-induced activity increases for positive pictures
(D+1 > D−1, positive > negative)
 Amygdala 18 −1 −20 3.26 0.028
 Insula −39 8 −11 4.42 0.002
 Dorsal ACC 3 −1 34 3.50 0.026
Short-term ketamine-induced activity decreases for positive pictures
(D−1 > D+1, positive > negative)
 No significant activation      
Long-term ketamine-induced activity increases for positive pictures
(D+7 > D−1, positive > negative)
 Posterior Insula −57 −1 −2 4.33 0.005
 Dorsal ACC −3 −4 34 3.94 0.024
Long-term ketamine-induced activity decreases for positive pictures
(D−1 > D+7, positive > negative)
 No significant activation      
ACC, anterior cingulate cortex; D, day; pSVC, pseudo stokes vector correlation.
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in line with our observations from the monetary incen-
tive delay task, and further indicate ketamine-induced 
increases in global vigilance. Most importantly, we found 
that amygdala, insula, and medial substantia nigra/ventral 
tegmental area activity in response to negative (vs. positive) 
emotional stimuli decreased after ketamine injection when 
compared with preinjection levels. It is known that, com-
pared with healthy controls, patients with major depressive 
disorder have increased responses in these brain regions 
when exposed to sad facial stimuli and decreased responses 
to happy facial stimuli (reviewed in Groenewold et al.6 and 
Stuhrmann et al.49). Our results show that ketamine may 
actually act against this overreactivity to aversive stimuli 
across limbic and mesolimbic regions, particularly specific 
of this pathology.50,51 Our investigations also provide a use-
ful replication of a recent functional magnetic resonance 
imaging study where treatment-resistant patients with 
major depressive disorder showed reduced responses in the 
caudate and insula when compared with healthy volunteers 
in a positive/negative emotion perception task, whereas 
ketamine administration restored activity in the caudate.16 
Importantly, our data give additional important information 
to these previous works by identifying the impact of ket-
amine in patients with major depressive disorder on neu-
ronal substrates involved in the active processing of both 
positive emotions and rewards. Here we tested these dis-
tinct facets of affective function using two dedicated tasks 
within the same patients. We relate that ketamine-induced 
modulation across mesolimbic regions (substantia nigra/
ventral tegmental area, ventral striatum, orbitofrontal cor-
tex) to improvement in motivated behavior, which may 
actively contribute to establishing and maintaining changes 
in mood. Indeed, our findings also demonstrate that these 
effects persist at least up to one week after ketamine injec-
tion suggesting, thereby, a lasting reorganization of neural 
networks by a single bolus of this drug.
Limitations
Our study has some limitations. First, the number of 
patients included in this study could be considered as rela-
tively low. It is nevertheless important to note that patients 
were selected based on strict inclusion criteria allowing us 
to investigate a rather homogenous patient population with 
major depressive disorder. In line with this argument, we 
found robust responses to ketamine both from the clinical 
and from the imaging perspective. A second potential lim-
itation is the lack of healthy volunteers as a control pop-
ulation. Although including these healthy controls would 
have provided us with additional information, this study 
focused on the question of ketamine-induced changes in 
neural networks in patients with major depressive disor-
der. Therefore, we believe that considering the patients as 
their own control, before ketamine injection, is an appro-
priate approach. Moreover, because of the absence of 
control group, we cannot rule out the effect of time and 
habituation to the tasks and also to the depression scale 
questionnaires. The comparison between different condi-
tions within each session minimizes this effect. Habituation 
would also lead to a linear increase or decrease of behavior 
and brain activity across time, but we clearly see a cut-off 
before and after the injection of ketamine and only few 
modifications between DAY+1 and DAY+7 sessions. A 
third limitation of our study is the lack of placebo control. 
Nevertheless, ketamine has been shown to exert a robust 
antidepressant effects when compared with placebo in all 
placebo-controlled trials in the field. Moreover, in our 
study, we systematically compared positive and negative 
emotions at each visit. The fact that we found changes in 
the positive but not in the negative emotions over time 
also argues against a potential placebo effect (i.e., we would 
expect changes in both positive and negative emotions in 
case of placebo effect). A fourth issue that could be consid-
ered as a potential limitation when comparing the results of 
our study with those of pioneering observations is that we 
have administered ketamine intravenously as a bolus dose 
over one minute, whereas most studies applied this drug 
through a period of 40 min of infusion. Although we can-
not exclude that pharmacokinetic or pharmacodynamics 
differences between these two administration protocols can 
give rise to different drug effects, the impact of our one-
minute-long ketamine administration on clinical depression 
scales appears to be comparable with previous studies in this 
field. Defining the most efficient administration modalities 
leading to the best clinical response is an important part of 
the current research agenda in this domain.17 Importantly, 
this rapid administration did not induce serious side effects 
necessitating clinical intervention. A fifth important issue 
that needs to be addressed in the future is the potential 
for sex-specific differences in responsiveness to ketamine. 
Indeed, recent meta-analysis suggests that males were a pre-
dictor of antidepressant response at 7 days after ketamine 
injection.11 Although no such differences appeared between 
male and female participants regarding the antidepressant 
and network effects of ketamine, our pilot study, including 
a limited number of patients, was not designed to test for 
potential sex-specific effects. Finally, an important remaining 
question is whether the functional changes induced by ket-
amine in reward and emotional processing networks persist 
longer than the one-week period investigated in our study.
In conclusion, our results provide novel mechanistic 
insights into how ketamine improves mood in patients with 
major depressive disorder. The rapid and lasting action of 
this drug on mesolimbic neural networks to reset pathologic 
reward and emotional processing points toward a potent 
role of ketamine in the modulation of neuronal plasticity.
Research Support
Supported by the National Center of Competence in 
Research (NCCR) Affective Sciences financed by the Swiss 




 http://pubs.asahq.org/anesthesiology/article-pdf/130/6/923/453736/20190600_0-00017.pdf by guest on 08 M
arch 2021
934 Anesthesiology 2019; 130:923–35 
PerioPerative Medicine
National Science Foundation (Geneva, Switzerland; grant 
No. 51NF40-104897) and hosted by the University of 
Geneva  (Geneva, Switzerland), and the Swiss National 
Science Foundation (grant No. 135554; to Dr. Kosel).
Competing Interests
The authors declare no competing interests.
Correspondence
Address correspondence to Dr. Sterpenich: Department 
of Neuroscience, University of Geneva Medical School, 
9 Chemin des Mines, 1202 Geneva, Switzerland. Virginie.
Sterpenich@unige.ch. Information on purchasing reprints 
may be found at www.anesthesiology.org or on the mast-
head page at the beginning of this issue. Anesthesiology’s 
articles are made freely accessible to all readers, for personal 
use only, 6 months from the cover date of the issue.
references
 1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters 
EE: Prevalence, severity, and comorbidity of 12-month 
DSM-IV disorders in the National Comorbidity Survey 
Replication. Arch Gen Psychiatry 2005; 62:617–27
 2. Krishnan V, Nestler EJ: The molecular neurobiology of 
depression. Nature 2008; 455:894–902
 3. Diener C, Kuehner C, Brusniak W, Ubl B, Wessa M, 
Flor H: A meta-analysis of neurofunctional imaging 
studies of emotion and cognition in major depression. 
Neuroimage 2012; 61:677–85
 4. Hägele C, Schlagenhauf F, Rapp M, Sterzer P, Beck A, 
Bermpohl F, Stoy M, Ströhle A, Wittchen HU, Dolan 
RJ, Heinz A: Dimensional psychiatry: Reward dys-
function and depressive mood across psychiatric disor-
ders. Psychopharmacology (Berl) 2015; 232:331–41
 5. Leppänen JM: Emotional information processing in 
mood disorders: A review of behavioral and neuroim-
aging findings. Curr Opin Psychiatry 2006; 19:34–9
 6. Groenewold NA, Opmeer EM, de Jonge P, Aleman 
A, Costafreda SG: Emotional valence modulates brain 
functional abnormalities in depression: Evidence from 
a meta-analysis of fMRI studies. Neurosci Biobehav 
Rev 2013; 37:152–63
 7. Jick H, Kaye JA, Jick SS: Antidepressants and the risk of 
suicidal behaviors. JAMA 2004; 292:338–43
 8. Berman RM, Cappiello A, Anand A, Oren DA, 
Heninger GR, Charney DS, Krystal JH: Antidepressant 
effects of ketamine in depressed patients. Biol Psychiatry 
2000; 47:351–4
 9. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli 
R, Luckenbaugh DA, Charney DS, Manji HK: A ran-
domized trial of an N-methyl-D-aspartate antagonist 
in treatment-resistant major depression. Arch Gen 
Psychiatry 2006; 63:856–64
 10. Fond G, Loundou A, Rabu C, Macgregor A, Lançon 
C, Brittner M, Micoulaud-Franchi JA, Richieri R, 
Courtet P, Abbar M, Roger M, Leboyer M, Boyer L: 
Ketamine administration in depressive disorders: A sys-
tematic review and meta-analysis. Psychopharmacology 
(Berl) 2014; 231:3663–76
 11. Coyle CM, Laws KR: The use of ketamine as an anti-
depressant: A systematic review and meta-analysis. 
Hum Psychopharmacol 2015; 30:152–63
 12. Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, 
Luckenbaugh DA, Brutsche N, Herscovitch P, Manji 
HK, Zarate CA Jr, Drevets WC: Neural correlates of 
rapid antidepressant response to ketamine in treat-
ment-resistant unipolar depression: A preliminary posi-
tron emission tomography study. Biol Psychiatry 2013; 
73:1213–21
 13. Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, 
Luckenbaugh DA, Brutsche N, Herscovitch P, Drevets 
WC, Zarate CA Jr: Neural correlates of rapid anti-
depressant response to ketamine in bipolar disorder. 
Bipolar Disord 2014; 16:119–28
 14. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, 
Roiser JP, Zarate CA: Anti-anhedonic effect of ket-
amine and its neural correlates in treatment-resistant 
bipolar depression. Transl Psychiatry 2014; 4:e469
 15. Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, 
Roiser JP, Zarate CA Jr: Neural correlates of change 
in major depressive disorder anhedonia follow-
ing open-label ketamine. J Psychopharmacol 2015; 
29:596–607
 16. Murrough JW, Collins KA, Fields J, DeWilde KE, 
Phillips ML, Mathew SJ, Wong E, Tang CY, Charney 
DS, Iosifescu DV: Regulation of neural responses to 
emotion perception by ketamine in individuals with 
treatment-resistant major depressive disorder. Transl 
Psychiatry 2015; 5:e509
 17. Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz 
J, Averill C, DeWilde KE, Wong E, Anticevic A, 
Tang CY, Iosifescu DV, Charney DS, Murrough JW: 
Ketamine Treatment and Global Brain Connectivity in 
Major Depression. Neuropsychopharmacology 2017; 
42:1210–9
 18. Knutson B, Westdorp A, Kaiser E, Hommer D: FMRI 
visualization of brain activity during a monetary incen-
tive delay task. Neuroimage 2000; 12:20–7
 19. Sterpenich V, Schwartz S, Maquet P, Desseilles M: 
Ability to maintain internal arousal and motivation 
modulates brain responses to emotions. PLoS One 
2014; 9:e112999
 20. Cardinal RN, Parkinson JA, Hall J, Everitt BJ: Emotion 
and motivation: The role of the amygdala, ventral stri-
atum, and prefrontal cortex. Neurosci Biobehav Rev 
2002; 26:321–52
 21. Adolphs R: Neural systems for recognizing emotion. 
Curr Opin Neurobiol 2002; 12:169–77




 http://pubs.asahq.org/anesthesiology/article-pdf/130/6/923/453736/20190600_0-00017.pdf by guest on 08 M
arch 2021
 Anesthesiology 2019; 130:923–35 935
Ketamine and Depression
Sterpenich et al.
 22. LeDoux JE: Evolution of human emotion: A view 
through fear. Prog Brain Res 2012; 195:431–42
 23. Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, 
Menéndez-González M, Pöppel E: Dopaminergic reward 
system: A short integrative review. Int Arch Med 2010; 3:24
 24. World MA: World Medical Association Declaration 
of Helsinki: Ethical principles for medical research 
involving human subjects. JAMA 2013; 310: 2191–4
 25. Vidal S, Gex-Fabry M, Bancila V, Michalopoulos G, 
Warrot D, Jermann F, Dayer A, Sterpenich V, Schwartz 
S, Vutskits L, Khan N, Aubry JM, Kosel M: Efficacy 
and safety of a rapid intravenous injection of ketamine 
0.5 mg/kg in treatment-resistant major depression: An 
open 4-week longitudinal study. J Clin Psychopharmacol 
2018; 38:590–7
 26. Montgomery SA, Asberg M: A new depression scale 
designed to be sensitive to change. Br J Psychiatry 
1979; 134:382–9
 27. Hamilton M: A rating scale for depression. J Neurol 
Neurosurg Psychiatry 1960; 23: 56–62
 28. Beck AT, Beamesderfer A: Assessment of depression: 
The depression inventory. Basel, Karger 1974; 7:151–69
 29. Bradley MM, Lang PJ: Measuring emotion: The self-as-
sessment manikin and the semantic differential. J Behav 
Ther Exp Psychiatry 1994; 25:49–59
 30. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, 
Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M: 
Automated anatomical labeling of activations in SPM 
using a macroscopic anatomical parcellation of the 
MNI MRI single-subject brain. Neuroimage 2002; 
15:273–89
 31. Russo SJ, Nestler EJ: The brain reward circuitry in 
mood disorders. Nat Rev Neurosci 2013; 14:609–25
 32. D’Ardenne K, McClure SM, Nystrom LE, Cohen 
JD: BOLD responses reflecting dopaminergic signals 
in the human ventral tegmental area. Science 2008; 
319:1264–7
 33. Knutson B, Fong GW, Adams CM, Varner JL, Hommer 
D: Dissociation of reward anticipation and out-
come with event-related fMRI. Neuroreport 2001; 
12:3683–7
 34. Knutson B, Bhanji JP, Cooney RE, Atlas LY, Gotlib 
IH: Neural responses to monetary incentives in major 
depression. Biol Psychiatry 2008; 63:686–92
 35. Lutz K, Widmer M: What can the monetary incentive 
delay task tell us about the neural processing of reward 
and punishment. NAN 2014; 3:33–45
 36. Mir P, Trender-Gerhard I, Edwards MJ, Schneider SA, 
Bhatia KP, Jahanshahi M: Motivation and movement: 
The effect of monetary incentive on performance 
speed. Exp Brain Res 2011; 209:551–9
 37. Joormann J, Siemer M: Memory accessibility, mood 
regulation, and dysphoria: Difficulties in repairing sad 
mood with happy memories? J Abnorm Psychol 2004; 
113:179–88
 38. Hegerl U, Hensch T: The vigilance regulation model 
of affective disorders and ADHD. Neurosci Biobehav 
Rev 2014; 44:45–57
 39. Henriques JB, Glowacki JM, Davidson RJ: Reward fails 
to alter response bias in depression. J Abnorm Psychol 
1994; 103:460–6
 40. Daniel R, Pollmann S: A universal role of the ven-
tral striatum in reward-based learning: Evidence 
from human studies. Neurobiol Learn Mem 2014; 
114:90–100
 41. Kahnt T, Heinzle J, Park SQ, Haynes JD: The neural 
code of reward anticipation in human orbitofrontal 
cortex. Proc Natl Acad Sci USA 2010; 107:6010–5
 42. Arrondo G, Segarra N, Metastasio A, Ziauddeen H, 
Spencer J, Reinders NR, Dudas RB, Robbins TW, 
Fletcher PC, Murray GK: Reduction in ventral striatal 
activity when anticipating a reward in depression and 
schizophrenia: A replicated cross-diagnostic finding. 
Front Psychol 2015; 6:1280
 43. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai 
HC, Finkelstein J, Kim SY, Adhikari A, Thompson KR, 
Andalman AS, Gunaydin LA, Witten IB, Deisseroth 
K: Dopamine neurons modulate neural encoding and 
expression of depression-related behaviour. Nature 
2013; 493:537–41
 44. Schlaepfer TE, Bewernick BH, Kayser S, Mädler B, 
Coenen VA: Rapid effects of deep brain stimulation for 
treatment-resistant major depression. Biol Psychiatry 
2013; 73:1204–12
 45. Bewernick BH, Kayser S, Sturm V, Schlaepfer TE: 
Long-term effects of nucleus accumbens deep brain 
stimulation in treatment-resistant depression: Evidence 
for sustained efficacy. Neuropsychopharmacology 
2012; 37:1975–85
 46. Hunt MJ, Kessal K, Garcia R: Ketamine induces dopa-
mine-dependent depression of evoked hippocampal 
activity in the nucleus accumbens in freely moving rats. 
J Neurosci 2005; 25:524–31
 47. Usun Y, Eybrard S, Meyer F, Louilot A: Ketamine 
increases striatal dopamine release and hyperlocomotion 
in adult rats after postnatal functional blockade of the 
prefrontal cortex. Behav Brain Res 2013; 256:229–37
 48. Joormann J, Gotlib IH: Selective attention to emotional 
faces following recovery from depression. J Abnorm 
Psychol 2007; 116:80–5
 49. Stuhrmann A, Suslow T, Dannlowski U: Facial emotion 
processing in major depression: A systematic review of 
neuroimaging findings. Biol Mood Anxiety Disord 
2011; 1:10
 50. Disner SG, Beevers CG, Haigh EA, Beck AT: Neural 
mechanisms of the cognitive model of depression. Nat 
Rev Neurosci 2011; 12:467–77
 51. Roiser JP, Elliott R, Sahakian BJ: Cognitive mechanisms 
of treatment in depression. Neuropsychopharmacology 
2012; 37:117–36




 http://pubs.asahq.org/anesthesiology/article-pdf/130/6/923/453736/20190600_0-00017.pdf by guest on 08 M
arch 2021
